LFCR Lifecore Biomedical
- 6.570
- -0.080-1.20%
- 6.570
- 0.0000.00%
Lifecore Biomedical News
Lifecore Biomedical Changes Executive Incentives to Stock Awards
What Made White Falcon Hold Lifecore Biomedical (LFCR)?
Lifecore Biomedical Faces Nasdaq Delisting Challenges
Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report
CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) (the "Company") announced today that, on April 15, 2024, the Company received a notification letter (the "Notice") from the
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Do You Believe in the Upside Trajectory of Lifecore Biomedical (LFCR)?
Lifecore Biomedical Sees FY24 Rev $125M-$130M >LFCR
Lifecore Biomedical Sees FY24 Rev $125M-$130M >LFCR
Press Release: Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Pro
Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024
Lifecore Biomedical (LFCR) said Tuesday that Ernst & Young LLP declined to be reappointed as the company's independent registered public accounting firm for its fiscal year ending May 26, 2024, follow
Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), announced today
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Lifecore Biomedical Announces New CEO and Equity Inducement Plan
Dow Surges 350 Points; Fed Holds Rates Steady
U.S. stocks traded higher toward the end of trading, after the Federal Reserve left rates unchanged. The Dow traded up 0.91% to 39,467.76 while the NASDAQ rose 1.08% to 16,341.42. The S&P 500 also ros
Top Midday Decliners
Lifecore Biomedical (LFCR) said Wednesday it has decided to continue with its standalone strategic plan after evaluating various alternatives, including reviewing more than 75 potential buyers. The co
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve. The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P
US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views
U.S. stocks traded slightly lower this morning, ahead of interest-rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow traded down 0.01% to 39,106.88 while the NASDA
Lifecore Biomedical Falls On Approval Of Strategic Alternatives, Appointment Of CEO
JAGX and GNPX Among Health Care Movers
Lifecore Shares Slide After Strategic Review Ends With No Deal
By Colin Kellaher Lifecore Biomedical shares lost nearly a quarter of their value in early trading Wednesday after the contract development and manufacturing organization said it would remain a stand
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersEtao International Co (NASDAQ:ETAO) shares increased by 180.5% to $0.4 during Wednesday's pre-market session. The company's market cap stands at $40.4 million. Jaguar Health (NASDAQ:JAGX) stock
Analysis
Price Target
No Data
